Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Efficacy of NCP112 in Healthy Volunteers
NCT05638165Phase 1Completed
- Sponsor
- NovaCell Technology
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NCP112 in atopic dermatitis (AD) (2 cohorts), sponsored by NovaCell Technology. Primary endpoint: Safety and Tolerability. Started Oct 2021; status: completed.
02
Drugs
NCP112
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05638165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638165.